BARDA Signs Biodefense Contracts With GSK And Soligenix
This article was originally published in The Pink Sheet Daily
Under a pair of agreements announced Sept. 19, the HHS unit will stockpile 60,000 doses of GSK’s inhalation anthrax treatment and will fund development of a treatment for GI acute radiation syndrome by New Jersey biotech Soligenix.
You may also be interested in...
BARDA’s Clinical Studies Network aims to reduce the number of countermeasure development failures.
After three months of battling, with lupus drug Benlysta still struggling, Human Genome Sciences accepted a modestly increased sales offer from partner GlaxoSmithKline.
Each week, “The Pink Sheet” presents commentary on some of the week’s most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at http://invivoblog.blogspot.com.